

Annamaria Biroccio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8711925/publications.pdf>

Version: 2024-02-01

102
papers

5,415
citations

76196

40
h-index

91712

69
g-index

105
all docs

105
docs citations

105
times ranked

7233
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. <i>EMBO Molecular Medicine</i> , 2022, 14, e14501.	3.3	13
2	TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer. <i>Cancer Letters</i> , 2022, 533, 215607.	3.2	9
3	Identification of Effective Anticancer G-Quadruplex-Targeting Chemotypes through the Exploration of a High Diversity Library of Natural Compounds. <i>Pharmaceutics</i> , 2021, 13, 1611.	2.0	12
4	Synthesis and Characterization of Bis-Triazolyl-Pyridine Derivatives as Noncanonical DNA-Interacting Compounds. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11959.	1.8	5
5	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1830.	1.7	2
6	Exploring the Interaction between the SWI/SNF Chromatin Remodeling Complex and the Zinc Finger Factor CTCF. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8950.	1.8	14
7	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 111.	3.5	14
8	Trifunctionalized Naphthalene Diimides and Dimeric Analogues as G-Quadruplex-Targeting Anticancer Agents Selected by Affinity Chromatography. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1964.	1.8	20
9	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 149, 105337.	1.9	15
10	BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. <i>Nature Communications</i> , 2019, 10, 3143.	5.8	141
11	Insights into telomeric G-quadruplex DNA recognition by HMGB1 protein. <i>Nucleic Acids Research</i> , 2019, 47, 9950-9966.	6.5	38
12	BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells. <i>Genes</i> , 2019, 10, 697.	1.0	13
13	Emerging roles of telomeric chromatin alterations in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 21.	3.5	30
14	TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. <i>Nucleic Acids Research</i> , 2019, 47, 3365-3382.	6.5	34
15	Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. <i>EMBO Molecular Medicine</i> , 2019, 11, e9982.	3.3	26
16	Dyads of G-Quadruplex Ligands Triggering DNA Damage Response and Tumour Cell Growth Inhibition at Subnanomolar Concentration. <i>Chemistry - A European Journal</i> , 2019, 25, 11085-11097.	1.7	14
17	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2. <i>EMBO Journal</i> , 2019, 38, .	3.5	49
18	Tailoring a lead-like compound targeting multiple G-quadruplex structures. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 295-306.	2.6	24

#	ARTICLE	IF	CITATIONS
19	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 996.	2.7	75
20	Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 57.	3.5	140
21	Tandem application of ligand-based virtual screening and G4-OAS assay to identify novel G-quadruplex-targeting chemotypes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1341-1352.	1.1	35
22	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3626-3635.	2.9	24
23	<scp>BRCA</scp> 1 and <scp>BRCA</scp> 2 tumor suppressors protect against endogenous acetaldehyde toxicity. <i>EMBO Molecular Medicine</i> , 2017, 9, 1398-1414.	3.3	57
24	EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1362-1370.	1.1	17
25	SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage. <i>Nucleic Acids Research</i> , 2017, 45, 1820-1834.	6.5	43
26	Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 189.	3.5	30
27	Patient-derived xenografts: a relevant preclinical model for drug development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 189.	3.5	109
28	Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells. <i>Biochimie</i> , 2016, 125, 223-231.	1.3	21
29	The telomeric protein AKTIP interacts with A- and B-type lamins and is involved in regulation of cellular senescence. <i>Open Biology</i> , 2016, 6, 160103.	1.5	29
30	A bimodal fluorescent and photocytotoxic naphthalene diimide for theranostic applications. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 7238-7249.	1.5	25
31	Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance. <i>Nucleic Acids Research</i> , 2016, 44, 1579-1590.	6.5	40
32	Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds. <i>Molecular Cell</i> , 2016, 61, 449-460.	4.5	185
33	Anacardic acid and thyroid hormone enhance cardiomyocytes production from undifferentiated mouse ES cells along functionally distinct pathways. <i>Endocrine</i> , 2016, 53, 681-688.	1.1	7
34	Abstract 266: The G-quadruplex ligand EMICORON potentiates the antitumor efficacy of chemotherapy on colon cancer experimental models. , 2016, , .		0
35	Identification of novel interactors of human telomeric G-quadruplex DNA. <i>Chemical Communications</i> , 2015, 51, 2964-2967.	2.2	31
36	Looking for Efficient G-quadruplex Ligands: Evidence for Selective Stabilizing Properties and Telomere Damage by Drug-Like Molecules. <i>ChemMedChem</i> , 2015, 10, 640-649.	1.6	46

#	ARTICLE	IF	CITATIONS
37	A basal level of DNA damage and telomere deprotection increases the sensitivity of cancer cells to G-quadruplex interactive compounds. <i>Nucleic Acids Research</i> , 2015, 43, 1759-1769.	6.5	15
38	Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2541-2551.	1.9	27
39	AKTIP/Ft1, a New Shelterin-Interacting Factor Required for Telomere Maintenance. <i>PLoS Genetics</i> , 2015, 11, e1005167.	1.5	38
40	Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex. <i>Frontiers in Chemistry</i> , 2014, 2, 54.	1.8	24
41	A novel pathway links telomeres to NK-cell activity. <i>Oncolmmunology</i> , 2014, 3, e27358.	2.1	8
42	Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 81.	3.5	32
43	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. <i>Nucleic Acids Research</i> , 2014, 42, 2945-2957.	6.5	45
44	Evidence for G-quadruplex in the promoter of VEGFR-2 and its targeting to inhibit tumor angiogenesis. <i>Nucleic Acids Research</i> , 2014, 42, 14083-14083.	6.5	0
45	Shading the TRF2 Recruiting Function: A New Horizon in Drug Development. <i>Journal of the American Chemical Society</i> , 2014, 136, 16708-16711.	6.6	23
46	Design and synthesis of a new dimeric xanthone derivative: enhancement of G-quadruplex selectivity and telomere damage. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 9572-9582.	1.5	14
47	Exploring the Chemical Space of G-Quadruplex Binders: Discovery of a Novel Chemotype Targeting the Human Telomeric Sequence. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9646-9654.	2.9	48
48	On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 68.	3.5	22
49	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. <i>Nature Cell Biology</i> , 2013, 15, 818-828.	4.6	99
50	β -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β -catenin signaling. <i>Oncogene</i> , 2013, 32, 5066-5077.	2.6	79
51	Methods of studying telomere damage induced by quadruplex-ligand complexes. <i>Methods</i> , 2012, 57, 93-99.	1.9	16
52	Aromatic Core Extension in the Series of N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands: Increased Telomere Damage, Antitumor Activity, and Strong Selectivity for Neoplastic over Healthy Cells. <i>ChemMedChem</i> , 2012, 7, 2144-2154.	1.6	33
53	Shooting for Selective Druglike G-Quadruplex Binders: Evidence for Telomeric DNA Damage and Tumor Cell Death. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9785-9792.	2.9	53
54	N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands Have Selective Antiproliferative Effects on Cancer Cells and Induce Telomere Damage. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1140-1156.	2.9	51

#	ARTICLE	IF	CITATIONS
55	Aromatase Inhibitor Exemestane has Antiproliferative Effects on Human Mesothelioma Cells. <i>Journal of Thoracic Oncology</i> , 2011, 6, 583-591.	0.5	10
56	Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. <i>Journal of Translational Medicine</i> , 2011, 9, 125.	1.8	11
57	DNA Damage Persistence as Determinant of Tumor Sensitivity to the Combination of Topo I Inhibitors and Telomere-Targeting Agents. <i>Clinical Cancer Research</i> , 2011, 17, 2227-2236.	3.2	33
58	Smad-Interacting Protein-1 and MicroRNA 200 Family Define a Nitric Oxide-Dependent Molecular Circuitry Involved in Embryonic Stem Cell Mesendoderm Differentiation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 898-907.	1.1	26
59	Inhibition of PARP activity by PJ-4 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. <i>Journal of Cellular Physiology</i> , 2010, 222, 401-410.	2.0	21
60	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. <i>Oncogene</i> , 2010, 29, 6280-6293.	2.6	103
61	Antiproliferative effect of Aurora kinase targeting in mesothelioma. <i>Lung Cancer</i> , 2010, 70, 271-279.	0.9	20
62	TRF2 and Apollo Cooperate with Topoisomerase 2 β to Protect Human Telomeres from Replicative Damage. <i>Cell</i> , 2010, 142, 230-242.	13.5	155
63	Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. <i>Nucleic Acids Research</i> , 2009, 37, 5353-5364.	6.5	152
64	β -Arrestin links endothelin A receptor to β -catenin signaling to induce ovarian cancer cell invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2806-2811.	3.3	159
65	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7284-7291.	3.2	82
66	β -Glutamylcysteine Synthetase Mediates the c-Myc-Dependent Response to Antineoplastic Agents in Melanoma Cells. <i>Molecular Pharmacology</i> , 2007, 72, 1015-1023.	1.0	13
67	Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. <i>Prostate</i> , 2007, 67, 1475-1485.	1.2	21
68	Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. <i>Journal of Clinical Investigation</i> , 2007, 117, 3236-3247.	3.9	212
69	TRF2 inhibition triggers apoptosis and reduces tumorigenicity of human melanoma cells. <i>European Journal of Cancer</i> , 2006, 42, 1881-1888.	1.3	62
70	c-Myc Phosphorylation Is Required for Cellular Response to Oxidative Stress. <i>Molecular Cell</i> , 2006, 21, 509-519.	4.5	175
71	Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. <i>Cell Death and Differentiation</i> , 2005, 12, 1429-1438.	5.0	124
72	Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. <i>Journal of Cellular Physiology</i> , 2005, 204, 463-469.	2.0	38

#	ARTICLE	IF	CITATIONS
73	Potential of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. <i>Cancer Biology and Therapy</i> , 2005, 4, 866-871.	1.5	15
74	Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. <i>Molecular Pharmacology</i> , 2004, 66, 1138-1146.	1.0	134
75	Telomerase as a new target for the treatment of hormone-refractory prostate cancer. <i>Endocrine-Related Cancer</i> , 2004, 11, 407-421.	1.6	34
76	In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. <i>International Journal of Cancer</i> , 2004, 110, 767-774.	2.3	25
77	Glutathione Depletion Induced by c-Myc Downregulation Triggers Apoptosis on Treatment with Alkylating Agents. <i>Neoplasia</i> , 2004, 6, 195-206.	2.3	45
78	Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. <i>Neoplasia</i> , 2004, 6, 195-206.	2.3	13
79	?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. <i>International Journal of Cancer</i> , 2003, 104, 243-250.	2.3	72
80	The future of antisense therapy: combination with anticancer treatments. <i>Oncogene</i> , 2003, 22, 6579-6588.	2.6	79
81	Che-1 Arrests Human Colon Carcinoma Cell Proliferation by Displacing HDAC1 from the p21 Promoter. <i>Journal of Biological Chemistry</i> , 2003, 278, 36496-36504.	1.6	46
82	Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. <i>Molecular Pharmacology</i> , 2003, 63, 632-638.	1.0	27
83	Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. <i>British Journal of Cancer</i> , 2003, 89, 1091-1095.	2.9	5
84	Inhibition of c-Myc Oncoprotein Limits the Growth of Human Melanoma Cells by Inducing Cellular Crisis. <i>Journal of Biological Chemistry</i> , 2003, 278, 35693-35701.	1.6	34
85	Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 927-931.	0.8	274
86	Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor. <i>Molecular Pharmacology</i> , 2003, 63, 192-202.	1.0	42
87	Glutathione Influences c-Myc-induced Apoptosis in M14 Human Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 43763-43770.	1.6	47
88	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. <i>Molecular Pharmacology</i> , 2002, 61, 524-532.	1.0	132
89	Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1 mediated transcriptional activity. <i>FASEB Journal</i> , 2002, 16, 1453-1455.	0.2	117
90	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. <i>Clinical Science</i> , 2002, 103, 302S-305S.	1.8	24

#	ARTICLE	IF	CITATIONS
91	Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. <i>European Journal of Cancer</i> , 2002, 38, 2455-2462.	1.3	32
92	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. <i>International Journal of Cancer</i> , 2002, 98, 463-469.	2.3	87
93	Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. <i>Oncogene</i> , 2002, 21, 3011-3019.	2.6	29
94	c-Myc and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer. <i>American Journal of Pathology</i> , 2001, 158, 1289-1299.	1.9	122
95	C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells. <i>Molecular Pharmacology</i> , 2001, 60, 174-182.	1.0	82
96	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 473-483.	1.2	14
97	Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. <i>Cancer Gene Therapy</i> , 2001, 8, 459-468.	2.2	60
98	bcl-2 over-expression enhances NF- κ B activity and induces mmp-9 transcription in human MCF7ADR breast-cancer cells. , 2000, 86, 188-196.		89
99	Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and <i>in vivo</i> angiogenesis in a breast carcinoma line. <i>FASEB Journal</i> , 2000, 14, 652-660.	0.2	115
100	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. <i>Gene Therapy</i> , 1999, 6, 1064-1072.	2.3	31
101	bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant mcf7 cells. , 1999, 82, 125-130.		31
102	Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. <i>FASEB Journal</i> , 1997, 11, 947-953.	0.2	126